Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp (NASDAQ: PHIO) is a clinical-stage biotechnology pioneer developing next-generation immuno-oncology therapies using its proprietary INTASYL® RNAi platform. This page provides centralized access to official press releases, clinical trial updates, and strategic partnership announcements related to PHIO's innovative approach to enhancing immune cell function against cancer.
Investors and researchers will find timely updates on PHIO's progress in silencing immune checkpoint targets like PD-1 and TIGIT through its self-delivering siRNA technology. The resource covers key developments including clinical trial milestones, collaborative research findings, and regulatory advancements for therapies like lead candidate PH-762.
Content spans multiple categories essential for tracking biopharmaceutical innovation: clinical trial results, research collaborations with institutions like Gustave Roussy, intellectual property updates, and technology licensing agreements. Each update is sourced directly from company disclosures to ensure reliability.
Bookmark this page for streamlined monitoring of PHIO's advancements in RNAi-based cancer therapeutics. Check regularly for new developments in their mission to overcome tumor-induced immunosuppression through precision gene silencing.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced the closing of a private placement, issuing 4,560,928 shares at $3.07 each, alongside warrants for 3,420,696 shares. This transaction raised approximately $14.0 million before expenses. The company plans to use the funds for its immuno-oncology research and general working capital. The warrants have an exercise price of $3.00 and are valid for five and a half years. Phio must file a registration statement covering the resale of the shares by February 1, 2021.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced a private placement to raise approximately $14.0 million by issuing 4,560,928 shares of common stock at $3.07 per share, along with warrants for 3,420,693 shares at an exercise price of $3.00. The placement is expected to close around January 25, 2021. Proceeds will be used for the development of immuno-oncology programs and general working capital. The company is required to file a registration statement within ten days for the resale of shares issued to investors.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. CEO Dr. Gerrit Dispersyn's corporate presentation will be available on-demand starting at 6 a.m. ET on January 11, 2021. The webcast can be accessed through the Company’s website and will be archived for 90 days. Phio focuses on advancing immuno-oncology therapeutics using its self-delivering RNAi platform, INTASYL™, aimed at tackling tumor-induced immune suppression.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology firm focused on immuno-oncology, announced that CEO Dr. Gerrit Dispersyn will present at the 3rd Annual Evercore ISI HealthCONx Conference, held virtually from December 1-3, 2020. Dr. Dispersyn's fireside chat is scheduled for December 3 at 3:05 p.m. ET, accessible via a live webcast. Phio's proprietary INTASYL™ RNAi platform aims to enhance immune responses against tumors. More details and a recorded version will be available on the company’s website post-event.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its financial results for Q3 2020, ending with $16.9 million in cash, up from $6.9 million in December 2019. The company increased R&D expenses to $1.3 million, attributed to preclinical studies. The net loss for the quarter was $2.3 million, or $0.40 per share, slightly higher than the $2.1 million net loss from the same quarter last year. Phio presented promising data at SITC 2020, showcasing its INTASYL RNAi technology's potential in enhancing cancer immunotherapy.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising results from a recent in vivo study demonstrating the enhanced efficacy of its INTASYL pipeline products when combined. The data, presented at the 35th Anniversary Annual Meeting of the Society for Immunotherapy of Cancer, shows that combining INTASYL compounds significantly improves tumor control compared to monotherapy. The compounds target PD-1, PD-L1, and TIGIT proteins linked to immune suppression in cancer. These findings suggest a potential breakthrough in the treatment of solid tumors, increasing the therapeutic options available for patients.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced three upcoming poster presentations at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), occurring virtually from November 9-14, 2020. The poster presentations highlight INTASYL compounds, a proprietary self-delivering RNAi therapeutic platform. Notably, findings include a study on combination treatment using INTASYL targeting TIGIT and PD-1/PD-L1, revealing enhanced tumor control. The archived presentation will be accessible in the "Investors – Events and Presentations" section of the Company's website.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced that CEO Dr. Gerrit Dispersyn will present at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Dr. Dispersyn's presentation will take place on September 16 at 11:30 a.m. ET. Investors can access the live webcast here, with an archived version available on the Company's website afterward. Phio focuses on developing innovative immuno-oncology therapeutics using its proprietary self-delivering RNAi platform, INTASYL™.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported its Q2 2020 financial results, highlighting significant advancements in its INTASYL™ RNAi therapeutic platform. Key developments include promising preclinical data from major conferences that demonstrate the safety and efficacy of INTASYL technology in targeting immune cells for cancer treatment. As of June 30, 2020, the company had $18.9 million in cash, up from $6.9 million at year-end 2019, aiding its operations for the next 12 months. The net loss was $1.7 million, a decrease compared to $2.0 million in Q2 2019.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced at the AACR 2020 Virtual Annual Meeting promising data from a study on PH-804, a TIGIT targeting INTASYL compound. The findings indicate significant tumor growth inhibition in a colorectal carcinoma model, showing PH-804's ability to silence TIGIT mRNA and enhance immune cell activation in the tumor microenvironment. This data supports the compound's potential as a viable alternative to anti-TIGIT antibodies.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
